{"id":"beta-blocker-digoxine-amiodarone","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Pulmonary toxicity (amiodarone)"},{"rate":null,"effect":"Thyroid dysfunction (amiodarone)"},{"rate":null,"effect":"Digoxin toxicity"},{"rate":null,"effect":"Photosensitivity (amiodarone)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Beta blockers reduce heart rate and contractility by blocking beta-adrenergic receptors. Digoxin increases cardiac contractility and slows AV node conduction through vagomimetic effects and Na+/K+-ATPase inhibition. Amiodarone is a broad-spectrum antiarrhythmic that blocks multiple ion channels (sodium, potassium, calcium) and has beta-blocking and calcium channel-blocking properties, making it effective for various arrhythmias.","oneSentence":"This is a combination therapy using three distinct cardiac drugs that work synergistically to reduce heart rate, increase cardiac contractility, and suppress arrhythmias.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:01.516Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation with rapid ventricular response"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Ventricular arrhythmias"},{"name":"Supraventricular tachycardia"}]},"trialDetails":[{"nctId":"NCT07447297","phase":"NA","title":"Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-01-02","conditions":"Atrial Fibrillation (AF), Diseases of the Circulatory System, Atrial Flutter","enrollment":520},{"nctId":"NCT07238452","phase":"PHASE4","title":"Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12-01","conditions":"Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation (AF)","enrollment":1056},{"nctId":"NCT06322017","phase":"NA","title":"Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-09","conditions":"Atrial Fibrillation","enrollment":294},{"nctId":"NCT05130268","phase":"PHASE4","title":"Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation","status":"COMPLETED","sponsor":"American Heart Association","startDate":"2021-10-29","conditions":"Atrial Fibrillation","enrollment":339},{"nctId":"NCT05391893","phase":"PHASE4","title":"Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation","status":"COMPLETED","sponsor":"Corewell Health South","startDate":"2020-06-19","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":444},{"nctId":"NCT06560047","phase":"NA","title":"Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure","status":"RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2024-08-28","conditions":"Atrial Fibrillation, Heart Failure","enrollment":1616},{"nctId":"NCT04542785","phase":"NA","title":"Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation Randomised Clinical Trial","status":"UNKNOWN","sponsor":"Holbaek Sygehus","startDate":"2021-03-31","conditions":"Atrial Fibrillation, Persistent, Atrial Fibrillation Chronic, Atrial Fibrillation","enrollment":350},{"nctId":"NCT04092621","phase":"PHASE4","title":"Rapid Atrial Fibrillation Treatment Strategy","status":"UNKNOWN","sponsor":"Our Lady of the Lake Hospital","startDate":"2019-09-16","conditions":"New Onset Atrial Fibrillation, Sepsis, Respiratory Failure","enrollment":40},{"nctId":"NCT02132767","phase":"PHASE3","title":"Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-05","conditions":"Postoperative Atrial Fibrillation","enrollment":523},{"nctId":"NCT03607123","phase":"","title":"Atrial Fibrillation With Sinus Node Dysfunction: Intensive Device Follow-up","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-07-04","conditions":"Sinus Node Dysfunction, Atrial Fibrillation","enrollment":200},{"nctId":"NCT00000556","phase":"PHASE3","title":"Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1995-03","conditions":"Arrhythmia, Atrial Fibrillation, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT01181414","phase":"PHASE4","title":"Spanish Atrial Fibrillation And Resynchronization Study","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2010-10","conditions":"Chronic Heart Failure, Cardiomyopathy, Dilated, Atrial Fibrillation","enrollment":60},{"nctId":"NCT00578617","phase":"NA","title":"Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-09","conditions":"Atrial Fibrillation, Arrhythmia","enrollment":60},{"nctId":"NCT01047566","phase":"PHASE4","title":"Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-04","conditions":"Atrial Fibrillation","enrollment":183},{"nctId":"NCT01411371","phase":"NA","title":"Catheter Ablation Versus Medical Treatment of AF in Heart Failure","status":"UNKNOWN","sponsor":"Barts & The London NHS Trust","startDate":"2005-03","conditions":"Atrial Fibrillation, Heart Failure","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":137,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Negative chronotropic drugs pharmacological treatment ."],"phase":"marketed","status":"active","brandName":"Beta blocker/digoxine/amiodarone","genericName":"Beta blocker/digoxine/amiodarone","companyName":"Hospital Clinic of Barcelona","companyId":"hospital-clinic-of-barcelona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Beta blockers, digoxine, and amiodarone are used to treat various conditions, including atrial fibrillation, heart failure, and respiratory failure, as indicated by ClinicalTrials.gov. Amiodarone, specifically, is a small molecule that acts as a HERG blocker, targeting the voltage-gated inwardly rectifying potassium channel KCNH2, according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}